2011

Welcome to Volume 10, Issue #9 (18 MAY 2011) of Pharma Marketing News.

All pharma companies face a communications crisis that rests on the changing role of the medical sales representative. This evolution has a direct impact on the obligations of the pharma marketing organizations to be both proactive and responsive in helping to protect their organizations from the threat of non-compliance. What can marketing do? This article offers a few thoughts from a physician's point.

Welcome to Volume 10, Issue #10 (8 JUNE 2011) of Pharma Marketing News.

A conversation with Casey Quinlan, 'Mighty Mouth' at Mighty Casey Media LLC, Zoe Dunn, Principal, Hale Advisors, Richard Meyer, Principal Consultant, Online Strategic Solutions, Jerry Hall, Digital Media Executive, Advisor to Pearescope, about engaging and marketing to women online, especially via social media, which some new media marketers claim is 'all about women.'

If pharma marketers are going to be successful engaging consumers (mostly women) via social media, then they need to be more sensitive about how they portray women in ads and very savvy about how they handle comments (if they allow comments).

Welcome to Volume 10, Issue #3 (17 FEBRUARY 2011) of Pharma Marketing News.

Despite dire predictions of 'PR failure,' the #rxsave Twitter chat hosted by @AstraZenecaUS on 15 February 2011 was a great success, which is pharma social media speak for 'did not crash and burn.' It was proof that a pharmaceutical company can indeed host meaningful Twitter chats.

Pharmaceutical marketers have jumped on the mobile application bandwagon as more and more companies roll out health-related applications for smartphones and touchpads such as Apple's iPhone and iPad. But will the FDA regulate certain smartphone apps as medical devices? This article discusses the regulatory and other issues associated with pharma developed or sponsored health apps.

Welcome to Volume 10, Issue #6 (30 MARCH 2011) of Pharma Marketing News.

In a recent blog post, PhRMA said 'Without Promotion Research will be Useless.' To support its case, PhRMA cited 'an interesting opinion editorial' in the latest edition of the Annals of Emergency Medicine -- the medical journal of the American College of Emergency Physicians (ACEP). In the op-ed, entitled 'Limiting Gifts, Harming Patients,' Emory University economist Paul Rubin, Ph.D. expressed concern that ACEP policy regarding Gifts to Emergency Physicians from Industry 'could have the unfortunate effect of limiting the exchange of critical information between medicine makers and physicians about the benefits and risks of new medicines, how to use them properly and how best to diagnose the right candidates for particular treatments.'